Home / Available CME / Redefining ARV Treatment
6:00 pm - 6:30 pm Registration
Credit Designation Statement
Redefining ARV Treatment
|
Presented By: |
|
About the Program
- Program Overview
- Program Objectives
- Commercial Support Acknowledgement
- Intended Audience
- Course Directors
- Faculty
- Live Program Locations
- Accreditation Statement
- Credit Designation Statement
- Policy on Faculty and Provider Disclosure
- Americans with Disabilities Act
- Request for Program Slides and Review
Program Overview
With more than 20 FDA-approved antiretrovirals (ARV) and 6 ARV classes, most of which are approved for use in ARV-naïve patients, health care providers caring for HIV-positive patients have multiple choices in first- and second-line ARV therapies. Choosing an appropriate ARV regimen in first- and second-line therapy is critical. An inappropriate ARV regimen is more likely to lead to (1) virologic failure, with resulting resistance that sets in motion a cascade of ARV drug and regimen issues which make it increasingly more difficult for the patient to succeed virologically and immunologically; and (2) short- or long-term tolerability or toxicity issues which may compromise the quality of the patient's life or lead to a premature, and unnecessary, death.
This case-based, highly interactive program is designed to provide clinicians of varying knowledge and skill levels with the requisite knowledge and clinical skills they need to choose the best first- and second-line regimen for each individual patient and improve the medical care of their patients.
This program is for health care providers who treat HIV-positive patients. It is tuition free and there are no prerequisites.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
Back to Top
Program Objectives
Upon completion of the program, participants will demonstrate the ability to:
-
Analyze and discuss key clinical research studies that have evaluated first- and second-line ARV regimens;
-
Use data regarding ARV tolerance, toxicities, pharmacokinetics, and other issues to improve ART success rates in first- and second-line ARV therapy;
-
Explain the role individual patient characteristics or desires may play in selecting ARV drugs and regimens;
-
Select ART regimens that maximize each patient's chance of long-term virologic and immunological success and avoidance of ARV-related morbidity and mortality.
Commercial Support Acknowledgement
This activity is supported by an unrestricted educational grant from Tibotec Therapeutics.
Back to Top
Intended Audience
This activity is intended for physicians, physicians' assistants, advanced practice nurses, and other healthcare professionals involved in the treatment and management of patients with HIV infection. There are no prerequisites.
Back to Top
Course Directors
John Bartlett, MD
Professor of Medicine,
Johns Hopkins School of Medicine
Baltimore, MarylandIan Frank, MD
Professor of Medicine,
Director, Antiretroviral Clinical Research
University of Pennsylvania
Philadelphia, Pennsylvania
Back to Top
Faculty
Calvin J. Cohen, MD, MS
Research Director,
CRI New England
Clinical Instructor,
Harvard Medical School
Boston, MassachusettsCharles Hicks, MD
Professor
Dept. of Medicine - Infectious Diseases
Duke University Medical Center
Durham, North CarolinaEric Daar, MD
Chief, Division of HIV Medicine,
Harbor-UCLA Medical Center,
Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, CaliforniaPaul Sax, MD
Clinical Director,
Brigham and Women's Division of
Infectious Diseases and HIV Program
Associate Professor of Medicine,
Harvard Medical School
Boston, MassachusettsRichard A. Elion , MD
Associate Professor of Clinical Medicine,
George Washington University Medical Center
Washington, DCAndrew Zolopa, MD
Associate Professor of Medicine,
Division of Infectious Diseases,
Stanford University School of Medicine
Palo Alto, California
Back to Top
Live Program Locations
To Register Click on Location or call (856) 506-5790
|
May 26, 2010 Wednesday |
June 3, 2010 Thursday |
June 10, 2010 Thursday |
Schedule for all programs:
6:00 pm - 6:30 pm Registration
6:30 pm - 8:30 pm Program Presentation
Please note that an online recording of this program will be available for CME credit in June, 2010.
Back to Top
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Back to Top
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 AMA PRA Category CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Back to Top
Policy on Faculty and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to topics of this educational activitiy, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course handout materials.
Americans with Disabilities Act
The Johns Hopkins University School fo Medicine fully complies with the legal requirements of the ADA and the rules and regulations there of. Please notify us if you have any special needs.
Back to Top
Request for Program Slides and Review
To request a copy of the program slides as well as further education on how to use the slides please Click Here to fill out a content request form. Please note that the program slides and education will only be available in June, 2010, after the last live dinner program has been completed.
Back to Top
Opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.
Copyright © 2008 The Johns Hopkins University School of Medicine. All rights reserved.
Share this page:
